
Opinion|Videos|March 6, 2025
Overview of Remibrutinib Phase 3 Clinical Trials in CSU
Panelists discuss how remibrutinib demonstrated rapid and sustained efficacy in the REMIX-1 and -2 trials through significant improvements in disease activity scores (UAS7, ISS7, HSS7) starting at week 1 and maintained through 52 weeks, with nearly half of patients achieving complete symptom resolution (UAS7 = 0) by week 52, while maintaining a favorable safety profile throughout the study period.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is notable about the efficacy and safety data from the REMIX-1 and -2 studies for remibrutinib?
- Significant change from baseline in UAS7 scores as early as week 1 and sustained through week 24, with similar trends for ISS7 and HSS7
- Primary end point met of superiority in change from baseline in UAS7 and ISS7/HSS7 at week 12 compared to placebo
- A higher proportion of patients with remibrutinib achieve UAS7 ≤ 6 and UAS7 = 0
- Safety consistent with previous findings
- There was additional data presented this year from the REMIX trials: long-term 52-week data. What new insights do this data reveal about remibrutinib?
- At week 24, patients receiving placebo were transitioned to remibrutinib; responses with remibrutinib were observed as early as the first week after switching and were sustained until the end of the study (28 weeks of treatment)
- Almost half of patients were completely free of itch and hives (UAS7 = 0) as assessed at week 52
- Safety profile favorable and consistent
- What is the clinical utility of the measures used in these studies (UAS7, ISS7, HSS7), and what is considered clinically meaningful for patients?
Advertisement
Related to this article

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.

Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.

Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.

Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5


